Altered glucose uptake in certain key regions in the brain may serve as a potential biomarker for key features in bipolar disorder.
Investigators observed whole-brain gray matter volumetric changes after treating patients with treatment-resistant depression with bi-temporal stimulation or right unilateral electroconvulsive therapy.
Psychologists and psychiatrists discuss the stigma of mental health disorders in practicing clinicians.
Researchers investigated subgroup responses to long-acting injectable medications haloperidol decanoate and paliperidone palmitate.
Per study data published in the Journal of Clinical Psychiatry, investigators hypothesized that the correlation between higher Frailty Index scores and increased caregiver burden was partially mediated by increased behavioral and psychological symptoms of dementia.
Emerging evidence has begun to elucidate the prevalence and outcomes associated with social anxiety disorder in schizophrenia.
Findings indicated that no significance of epidermal growth factor levels and fibroblast growth factor-2 levels were found in elderly patients with major depressive disorder.
No significant sex differences were found in the prevalence of eating disorders in children age 9 to 10.
Investigators compared trajectories of depressive symptoms in sexual-minority adolescents and heterosexual adolescents from age 10 to 21.
Patients with chronic pain and a history of physical and sexual abuse were found to be more likely to concurrently use benzodiazepine and opioids.
The investigational fatty acid amide hydrolase inhibitor PF-04457845 may decrease cannabis withdrawal symptoms and dependence in men.
The use of trazodone in older patients with dementia was associated with similar levels of risk for falls and fractures as atypical antipsychotics.
More than two-thirds of patients with serious psychological distress used outpatient mental health services in 2014 to 2015, an increase of 14.3% from 2004 to 2005.
Only 24.1% of lithium users met the standards from the International Society for Bipolar Disorders to screen for lithium levels and renal function every 3 months in older adults.
Sandoz and Pear Therapeutics announced the launch of reSET-O, a new digital therapeutic for patients aged ≥18 years with opioid use disorder (OUD) currently under clinician care.